



INVESTOR PRESENTATION

July 2020

Ofer Haviv, President & CEO

A large, circular graphic on the right side of the slide. It consists of several concentric circles with a glowing, starburst effect at the center. The background of the slide is dark blue with a pattern of binary code (0s and 1s) and hexagonal shapes, suggesting a technological or biological theme.

DECODING BIOLOGY

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For example, Evogene is using forward-looking statements in this presentation when it discusses its near-term value drivers, including statements to the effect that it will reach commercialization, regulatory approval or enter into collaboration agreements; its milestones for each of 2020, 2021 and 2022; its belief that its diverse portfolio mitigates the risk associated with each individual opportunity within its portfolio and in its product pipeline; and its estimated cash usage for its year ending December 31, 2020. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom, the extent of Evogene continuing to maintain its holdings in its subsidiary companies, whether Evogene is able to comply with regulatory requirements, the degree of Evogene's success at adapting to the continuous technological changes in its industries, and those factors and risks described in greater detail in Evogene's Annual Report on Form 20-F and in other reports it files and furnishes with the U.S. Securities and Exchange Commission and the Israel Securities Authority from time to time. In addition, Evogene relies, and expects to continue to rely, on third parties to conduct certain activities, such as its field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene may experience significant delays in the conduct of its activities. All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.


The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Agenda

- ✦ Introduction
- ✦ Fields of activity
- ✦ Technology
- ✦ Summary

Annex I - Evogene's Main Subsidiaries


Annex II - Financial Fundamentals



INTRODUCTION

Evogene at a glance...

What we do...	Revolutionizing life-science product development utilizing cutting-edge computational biology technologies.
Our technology	The CPB platform (Computational Predictive Biology) - incorporating deep scientific understandings together with big data and advanced artificial intelligence (AI) technologies to unlock the hidden value of biology.
Our product solutions	Solutions to direct & accelerate the discovery and development of products, based on the following core components: - MicroBoost AI – for product based on microbes - ChemPass AI – for product based on small molecules - GeneRator AI – for product based on genetic elements
Main target end-markets	1) Human Health: Microbiome-based therapies for: Immuno-oncology (\$243 B in 2026), Inflammatory Bowel Disorder (\$22.4 B in 2026), Irritable Bowel Syndrome (\$3.3 B in 2026), Medical cannabis (\$64 B in 2024) 2) Agriculture: Ag-biologicals (\$13.4 B in 2024), Ag-chemicals (\$70 B in 2022), Seed traits (\$37.5 B)
Business strategy	1) Collaboration – Joint development with leading companies for defined products using Evogene’s solutions 2) Subsidiaries – Establishment of independent entities focusing on a defined commercial field with an exclusive license to use the CPB platform
Our strategic partners	BASF, Bayer, Corteva and ICL (also via subsidiaries)
Main subsidiaries	AgPlenus – ag-chemicals, Biomica – human microbiome, Canonic – medical cannabis, Lavie Bio – ag-biologicals
Employees	Including subsidiaries - 121 (74% in R&D, 40 PhD’s) / In Evogene (solo) - 78 (65% in R&D (CPB), 20 PhD’s)
Cash position/Listing	Cash position (as of 31.3.2020) \$40.6 million; Listing - EVGN: NASDAQ (2013), TASE (2007)



OUR VISION

Revolutionizing life-science product development utilizing cutting edge computational biology technologies.


DECODING BIOLOGY

Life-science product development challenges

High cost, long time-to-market and low probability of success




Discovery and development costs of a new crop protection product



Source: Phillips McDougall, 2016

CDER'S* annual novel drug approvals: 2010-2019

In 2019, CDER approved 48 novel drugs. The 10-year graph below shows that from 2010 through 2018, CDER has averaged about 37 novel drug approvals per year.



Source: U.S. Food and Drug Administration

Time to develop a new crop protection product

	1995	2000	2005-8	2010-15
Number of years between the first synthesis and first sale of product	8.3	9.1	9.8	11.3

Source: Phillips McDougall, 2016

Worldwide total pharmaceutical R&D spend in 2010-2024



Source: Evaluate Pharma May 2019

*Center for Drug Evaluation and Research



HUMAN HEALTH



AGRICULTURE



INDUSTRIAL
APPLICATIONS

The opportunity

Utilize comprehensive and integrated computational biology to substantially increase the probability of success, while reducing the time and cost of life-science product development.


When biology meets disruptive technologies; introducing–

CPB[★] platform

Incorporating deep scientific understandings together with big data and advanced artificial intelligence technologies (AI), seeking to successfully discover & develop novel life-science based products.

Developed over two decades at an investment of tens of millions of dollars and validated through collaborations with industrial leaders


CPB[★] – Computational Predictive Biology



Tailor-made **solutions** for product development

The CPB platform provides tailor-made **solutions** for discovery and development for life-science products based on the following three core components:

- Microbes
- Small molecules
- Genetic elements



Business Model

1

Collaborations

Joint development with leading companies for defined products utilizing Evogene's unique solution. Later-stage development and commercialization of the product will likely be done by the partner.

Potential revenue for Evogene

- Licensing and research payments
 - Milestone payments
 - Revenue sharing
-

Main Business Model till 2014:



- GMO seed traits for yield and abiotic stress for wheat



- GMO seed traits for yield and abiotic stress for corn
- GMO seed traits for ASR resistance for soybean



- GMO seed traits for yield and abiotic stress for corn and soybean
- GMO (2013) and genome editing (2019) seed traits for fusarium resistance



- GMO seed traits for nematode resistance

Business Model



2

Subsidiaries

Establish independent entities focusing on a defined commercial field with an exclusive license to use Evogene's unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategic collaborations.

Potential revenue for Evogene

- Licensing and research payments
- Consolidated revenues
- Dividends (subject to profits generated by subsidiary)
- Sale of equity


Main Business Model from 2015:




A hand in a white lab glove is pouring a clear liquid from a glass beaker into a small glass vial. The liquid is captured mid-pour, creating a bright, star-like reflection on the surface of the vial. The background is a soft, out-of-focus blue and purple gradient.

FIELDS OF ACTIVITY


Potential fields of activity



Current life-science based products under development



Development & commercialization through subsidiaries and collaborations



Evogene group



Human Health



90%*

Microbiome based Therapeutics

- Immuno-oncology
- GI- gastrointestinal-related disorders
- MDRO – multi-drug resistant organisms



100%*

Medical Cannabis

- Stable high yield of specific compounds
- Stable high yield of total compounds

Agriculture



100%*

Ag Chemicals

- Herbicides
- Insecticides
- Fungicides



72%*

Ag Biologicals

- Bio-Stimulants
- Bio-Pesticides



Internal division of Evogene

Seed Traits

- Yield improvement and drought tolerance
- Plant disease
- Insect control

Industrial Applications



100%*

Castor Oil Production

- Castor seeds & growth protocol

*Evogene holdings in its applicable subsidiaries

Subsidiaries - expected main near-term value drivers

	2020		2021		2022
	 Extend pre-clinical study in immuno-oncology program	 Initiate first GMP production of drug candidates in immuno-oncology program	 Extend pre-clinical study in Inflammatory Bowel Disease (IBD) program	 Proof of concept, first in man study, in the immuno-oncology program	
	 Engagement with commercial partners for cultivation and production	 Demonstrate yield improvement in cannabis lines under development	 Pre-commercial activity towards commercialization in 2022	 Demonstrate clinical effects of a developed line, based on dedicated research with a medical institution	
	 Sign collaboration based on pre-Lead candidates from herbicide program	 Reach a 'Lead' in herbicide program	 Reach a POC for a herbicide tolerance gene trait, for a 'Lead' herbicide in development	 Licensing agreement of 'Lead' herbicide candidate	
	 Advance phase in bio-pesticide & bio-stimulant programs	 File for regulatory approval for a wheat bio-stimulant product	 Receive regulatory approval for a wheat bio-stimulant product	 Advance a wheat bio-stimulant product to pre-commercial activities with early-adopter farmers	

 Pipeline
  Regulation
  Collaboration
  Commercialization

* Additional milestone on slide 35

TECHNOLOGY


The **challenge** in creating life-science based products



The **challenge** in creating life-science based products

Common practice

Discovery – selection of product candidates mainly addressing efficacy



The **challenge** in creating life-science based products

Common practice

Discovery – selection of product candidates mainly addressing efficacy

Development – inefficient optimization & difficulty in addressing a single challenge without impairing others



- ✗ Low probability of success
- ✗ Long time to market
- ✗ High development costs





Evogene's AI-based solution: Discovery

A multi-attribute computational selection of product candidates, addressing relevant challenges using dedicated training data sets and AI.



Evogene's AI-based solution: Development

A multi-attribute computational analysis, addressing a specific development challenge of the selected candidate, without impairing its ability to address other product attributes.



Evogene's AI-based tailor-made solution

✦ Discovery

Computational prediction of candidates, to serve as the **product's core-component**, addressing multiple key product attributes.

✦ Development

Computational driven solution for guiding and assessing the optimization process of the **selected core component**, without impairing other key product attributes.





SUMMARY

Investment highlights



Technological platform and diverse product portfolio to mitigate the risk associated with life-science investments

Evogene offers the opportunity to invest in the technology of tomorrow, while its and its subsidiaries' diverse and advanced product portfolios may mitigate the risk associated with an individual opportunity.

Value creation through subsidiary

Example #1

In August 2019, Lavie Bio, secured a strategic investment from Corteva:

- \$10 million dollars in cash, and transfer of Corteva Inc.'s holdings in its subsidiary, Taxon Biosciences.
- in exchange for ~ 28% of Lavie Bio's shares.

Value creation through subsidiary

Example #2

Wholly owned subsidiary, AgPlenus, recently entered into a strategic collaboration with Corteva for the development of a new MoA (Mode-of-Action) herbicide.

Significant milestones expected

Biomica - Proof of concept, first in man study, in the immuno-oncology program, expected in 2021.

Canonic - Pre-commercial activity expected in 2021. Commercialization expected in 2022.


AgPlenus – Reach 'Lead' chemical, the basis for a new MoA herbicide, expected in 2020.

Lavie Bio – Advancement of a wheat bio-stimulant to pre-commercial activities with early-adopter farmers, expected in 2021. Commercialization expected in 2022.

A hand in a purple glove holds a glowing blue ring. From the ring, numerous rays of binary code (0s and 1s) emanate, creating a starburst effect. The background is a gradient of purple and blue.

THANK YOU!

evogene
DECODING BIOLOGY



Annex I: Evogene's Main Subsidiaries



HUMAN HEALTH

BIOMICA | CANONIC

Biomica's Mission

Discovery and development of novel therapies for microbiome-related human disorders using computational biology.

Product Pipeline



Immuno-oncology

BMC121

Combination therapy for cancer with checkpoint inhibitors

BMC127

Combination therapy for cancer with checkpoint inhibitors



GI related disorders

BMC321

| Inflammatory Bowel Disorder (IBD)

BMC322

| Inflammatory Bowel Disorder (IBD)

BMC426

| Irritable Bowel Syndrome (IBS)



MDRO (Multi Drug resistant organisms)

BMC201

| Clostridioides difficile infection (CDI)

* Sources can be found in 20-F filing



Immuno-Oncology Program – Preparation towards the anticipated first in man proof of concept clinical trials

(January 2020)

Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program

The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials

Rehovot, Israel – January 13, 2020

Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for the scale-up production of its drug candidates, microbial consortia BMC121 & BMC127 for its Immuno-Oncology program. This agreement will accelerate the Company's Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies.

Biose Industrie is a drug-GMP certified manufacturer of bacteria-based APIs and clinical and commercial products. Biomica engaged with Biose for the scale-up development and GMP production of a clinical batch of its drug candidates.

Milestones

2020

- Extend pre-clinical study in immuno-oncology program.
- Initiate first GMP production of drug candidates immuno-oncology program.

2021

- Proof of concept, first in man study, in the immuno-oncology program.
- Extend pre-clinical study in IBD program.



Canonic's Mission

Commercialize precise & stable medical cannabis products for better therapeutic effects using computational biology.

Product Pipeline



MetaYield

Stable enhancement of total plant compounds

- Increased compounds per plant
- Increased compounds per area



Precise

Stable enhancement of specific active compounds

- Medical indication focus
- Compound profile focus



Initiation of Breeding and Cultivation of Cannabis Varieties with Unique Genomic Profiles

(November 2019)

Canonix Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products

This announcement follows successfully importing a collection of widely genetically diverse cannabis lines, establishing specialized R&D facilities, and receiving regulatory approval from the Israeli Medical Cannabis Agency (IMCA)

Rehovot, Israel – November 6, 2019

Canonix, a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN) focused on the development of medical cannabis products, announces today the initiation of its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. The initiation of cannabis cultivation follows: (1) successfully importing widely genetically diverse cannabis lines originating from different territories, (2) establishment of cannabis dedicated R&D facilities, including greenhouses, a molecular lab and tissue culture rooms and (3) receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency (IMCA).



Milestones

2020

- Demonstrate yield improvement in cannabis lines under development.
- Engagement with commercial partners for cultivation and production.
- Conduct pre-clinical studies to support the development of Canonix's medical cannabis products.

2021

- Pre-commercial activity with first cannabis variety towards commercialization in 2022.
- Demonstrate clinical effects of Canonix varieties based on dedicated research with a medical institution.





AGRICULTURE

AgPlenus | Lavie Bio

AgPlenus Mission

Design of next generation effective, sustainable and safer crop protection products by leveraging computational biology.

Product Pipeline



Herbicide

Novel MOA (Mode-of-Action)

Existing MOA optimization



Insecticide

Novel SoA (Site-of-Action)

AI optimization



Fungicide

Existing MOA optimization



Strategic collaboration with Corteva for the development of novel herbicides

(March 2020)

Corteva Agriscience and AgPlenus Announce Collaboration for the Development of Novel Herbicides

**Collaboration to address rise in global weed resistance
using Corteva's product discovery and development
expertise and AgPlenus' internal novel herbicide pipeline**

**Wilmington, DE., USA and Rehovot, Israel – March 25,
2020**

Corteva Agriscience (NYSE: CTVA), a leading pure-play agriculture company, and AgPlenus, a subsidiary of Evogene Ltd., (NASDAQ: EVGN, TASE: EVGN), today announced that they have entered into a multi-year collaboration for the development of novel herbicides. The collaboration will combine Corteva's strengths in crop protection product discovery and development with AgPlenus' expertise in designing effective and sustainable crop protection products using predictive biology.

By leveraging their complementary expertise, Corteva and AgPlenus will address the rise of global weed resistance, created in-part by the absence of new modes of action (MoAs) for weed control over the past 30 years. Successful products resulting from the collaboration will enter a multi-billion-dollar market.



Milestones

2020

- ✓ Sign collaboration based on pre-Lead candidates from herbicide program.
- Reach a 'Lead' in herbicide program.

2021

- Reach a POC for a herbicide tolerance gene trait, for a 'Lead' herbicide in development.
- Licensing agreement of 'Lead' herbicide candidate.



Lavie Bio Mission

Improve food quality, sustainability and agricultural productivity through the introduction of microbiome based ag-biological products using computational biology.

Product Pipeline



Bio-Stimulants

Wheat

Corn



Bio-Pesticides

Mildew, fruit rots

Fusarium and seedlings disease

Bio-Insecticides



Corteva Investment in Lavie Bio

Corteva's investment included its holdings in its wholly owned subsidiary Taxon Biosciences and \$10 million to Lavie Bio.

(August 2019)

Corteva Agriscience to Invest in Evogene's Agriculture Biologicals Subsidiary, Lavie Bio

Investment Includes Equity and Corteva's Shares in Taxon Biosciences for Shares in Lavie Bio

Wilmington, Del., USA and Rehovot, Israel – Aug. 7, 2019

Corteva, Inc. (NYSE: CTVA), a leading pure-play agriculture company, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Corteva will make an investment in Evogene's agriculture biologicals subsidiary, Lavie Bio (Lavie). The transaction includes the exchange of all shares of Corteva's wholly owned subsidiary Taxon Biosciences along with an equity investment by Corteva in Lavie. As consideration for the Taxon Biosciences shares and equity investment, Corteva will be issued approximately 30 percent of Lavie's equity while Evogene will hold approximately 70 percent of Lavie's equity.

Taxon Biosciences' capabilities are expected to provide significant synergetic value to Lavie and accelerate the development of Lavie's products. Taxon Biosciences' assets, including a large microbial collection and product candidate pipeline, will be integrated into Lavie's pipeline, accelerating Lavie's 'biology driven design' approach and its product development.



Milestones

2020

- Advance phase in bio-pesticide & bio-stimulant programs.
- File for regulatory approval for a wheat bio-stimulant product.

2021

- Receive regulatory approval for a wheat bio-stimulant product.
- Advance a wheat bio-stimulant to pre-commercial activities with early-adopter farmers.





Annex II: Financial Fundamentals

Key Financials: Balance Sheet

Key Points:

- Consolidated cash position: ~\$40.6 million as of 31.03.2020
- No debt
- Estimated net cash usage for 2020 (without Lavie Bio): \$13-\$15 million
- Listed on TASE (2007) and NASDAQ (2013)

Thousands of US \$	31.03.2020	31.12.2019
Current Assets	42,875	49,027
Long-Term Assets	21,770	22,337*
Total Assets	64,645	71,364
Current Liabilities	4,488	5,746
Long-Term Liabilities	5,220	5,401
Equity attributable to equity holders of the Company	43,976	50,144
Non-controlling interest	10,961	10,073
Total Liabilities & Shareholders Equity	64,645	71,364

*~\$17 million attributed to intangible assets (net) following Corteva's investment in Lavie Bio